Even with the traditional post-Thanksgiving break fast approaching, buysiders say there is still plenty of demand to support companies in the IPO queue. But timing will be increasingly tight for those that haven't filed publicly by the end of this week.

The number of biotechs in the queue grew to 23 last week as three new names were added and one - ADMA Biologics Inc. (NASDAQ:ADMA) - slipped out the door. The antibody